4-Methylmorpholine → (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-hydroxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide

HRID 132965ノート

反応式

HRID 132965 の反応式
[NH2:1][C@@H:2]([CH2:30][C:31]1[CH:36]=[C:35]([F:37])[CH:34]=[C:33]([F:38])[CH:32]=1)[C@@H:3]([C@H:5]1[CH2:9][C@H:8]([O:10]C2C=CC=CN=2)[CH2:7][N:6]1C(C1C=CC=CC=1)C1C=CC=CC=1)[OH:4].[C:39]([NH:42][C@:43]1([C@@H:92]([CH2:94][CH3:95])[CH3:93])[CH2:47][CH2:46][N:45]([C@@H:48]([CH2:83][CH2:84][C:85]2[CH:90]=[CH:89][CH:88]=[CH:87][CH:86]=2)[C:49](N[C@@H](CC2C=C(F)C=C(F)C=2)[C@@H]([C@H]2C[C@@H](O)CN2C(C2C=CC=CC=2)C2C=CC=CC=2)O)=[O:50])[C:44]1=[O:91])(=[O:41])[CH3:40].C(N[C@]1([C@@H](CC)C)CCN([C@@H](CCC2C=CC=CC=2)C(O)=O)C1=O)(=O)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C(N[C@]1([C@@H](CC)C)CCN([C@@H](CCC2C=CC=CC=2)C(N[C@@H](CC2C=C(F)C=C(F)C=2)[C@@H]([C@H]2CCCCN2C(C2C=CC=CC=2)C2C=CC=CC=2)O)=O)C1=O)(=O)C.CN1CCOCC1>CN(C=O)C>[C:39]([NH:42][C@:43]1([C@@H:92]([CH2:94][CH3:95])[CH3:93])[CH2:47][CH2:46][N:45]([C@@H:48]([CH2:83][CH2:84][C:85]2[CH:86]=[CH:87][CH:88]=[CH:89][CH:90]=2)[C:49]([NH:1][C@@H:2]([CH2:30][C:31]2[CH:36]=[C:35]([F:37])[CH:34]=[C:33]([F:38])[CH:32]=2)[C@H:3]([OH:4])[C@H:5]2[CH2:9][C@@H:8]([OH:10])[CH2:7][NH:6]2)=[O:50])[C:44]1=[O:91])(=[O:41])[CH3:40]

参加物

8

実験手順

Step 14 (B): (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-1-((2R,4R)-1-benzhydryl-4-hydroxypyrrolidin-2-yl)-3-(3,5-difluorophenyl)-1-hydroxypropan-2-yl)-4-phenylbutanamide. To a solution of (S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-4-phenylbutanoic acid (Preparation A, 22.6 mg, 0.063 mmol) in DMF (1 mL) was added HATU (28.7 mg, 0.076 mmol). A solution of (3R,5R)-5-((1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl)-1-benzhydrylpyrrolidin-3-ol (Step 14 (A), 27.5 mg, 0.063 mmol) in DMF (1 mL) was then added, followed by N-methylmorpholine (24.2 μl, 0.221 mmol). The reaction mixture was stirred at rt for 3 h. pH 4 buffer was then added to quench. The mixture was extracted with ethyl acetate. The organic phase was washed with sat. aqueous NaCl, dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by reverse phase Prep HPLC to give the title compound (32 mg, 65% yield) as a slightly yellow oil: 1H NMR (CDCl3, 500 MHz) δ 0.88 (3H, d, J=10 Hz), 1.00 (3H, m), 1.07-1.18 (1H, m), 1.55-1.61 (1H, m), 1.72-1.78 (1H, m), 1.95-2.03 (4H, m), 2.05-2.11 (2H, m), 2.30 (2H, d, J=15 Hz), 2.38-2.47 (1H, m), 2.48-2.53 (1H, m), 2.64-2.70 (1H, m), 2.88 (1H, m), 3.03-3.08 (3H, m), 3.17-3.20 (1H, m), 3.49 (1H, s), 3.53-3.61 (3H, m), 3.91 (1H, d, J=10 Hz), 3.96 (3H, s), 4.11 (1H, m), 4.47 (1H, brd s), 4.96 (1H, brd s), 6.13 (1H, brd s), 6.58-6.67 (3H, m), 7.04-7.37 (10H, m), 7.49 (2H, m), 7.67 (2H, d, J=10 Hz). HPLC retention time: 1.67 min (method A). MS (ESI) (M+H)+ 781.35.

後処理

  1. additionbuffer was then added
  2. customto quench
  3. extractionThe mixture was extracted with ethyl acetate
  4. washThe organic phase was washed with sat. aqueous NaCl
  5. dry with materialdried (MgSO4)
  6. concentrationconcentrated in vacuo
  7. customThe crude mixture was purified by reverse phase Prep HPLC

出典と根拠

ORDレコード
ord-ae4f59e65419479dbad1a7a4543563c8
出典データセット
uspto-grants-2008_06
特許番号
US07388007B2

反応ノート

読み込み中…